United States

FFO (TTM)

FFO/share (TTM)

FFO/share Guidance

FFO (Quarter)

FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/FFO

Size (ft²)

Total Portfolio Occupancy

Retail is evolving, and we are here to lead. We intend to profit from the dislocation in retail real estate by investing in and redeveloping mispriced and misunderstood assets. SITE Centers seeks to produce compelling, sustainable results for stakeholders through creative and active management of retail real estate.

SITE Centers

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, SITC is classified as investment grade

Period: 2022 Q4

Years since IPO: 15/15,
FFO Growth: 13/15,
FFO/share Growth: 3/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q2

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q4

Years since IPO: 15/15,
FFO Growth: 13/15,
FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 12/15
            

Period: 2025 Q1

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 12/15
            

Period: 2025 Q2

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 12/15
            

Period: 2025 Q3

Years since IPO: 15/15,
FFO Growth: 0/15,
FFO/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 10/15,
Debt: 5/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's FFO

FFO Growth

Assessment of recent increases in FFO per share, indicating profitability

FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

HONG KONG , Nov. 7, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) published the preclinical research data for its novel antagonistic monoclonal antibody targeting IL-1RAP, AK135, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. The results demonstrated that AK135 effectively targets IL-1RAP and blocks three key pro-inflammatory signaling pathways—IL-1, IL-33, and IL-36 at their source, thereby halting the transmission of inflammatory signals.

Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB)

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, demonstrated promising monotherapy anti-tumor activity in patients with advanced solid tumors and generally well-tolerated safety profile Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, show potential for ctDNA as an early predictor for response to treatment with vilastobart in combination with atezolizumab in patients with MSS mCRC WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced new data across its portfolio, including preclinical data highlighting the best-in-class potential for Xilio's masked T cell engager platform and programs, as well as Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, and Phase 2 data related to circulating tumor DNA (ctDNA) for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4.

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today shared preclinical data at the 2025 Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and immune disorders, today announced updated clinical results evaluating agenT-797, alone and in combination with anti-PD-1 therapy, in patients with advanced solid tumors refractory to all approved treatments presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 (Late Breaking Abstract #1344).

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Pre-clinical data for IO Biotech's next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs) Pre-clinical data for IO Biotech's additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-β, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasis Data presented at the Society for Immunotherapy of Cancer's Annual Meeting NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced new pre-clinical data for IO Biotech's next vaccine candidate, IO112, and additional candidate, IO170, will be presented at the Society for Immunotherapy of Cancer's 40th Annual Meeting (SITC 2025) in Maryland on November 5-9, 2025. “This new data is extremely important for our development path as it points toward more potential indications for our novel, immune-modulatory therapeutic vaccines to treat patients with a range of cancers,” said Mai-Britt Zocca, PhD, President and CEO of IO Biotech.

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients –

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activation Robust immune responses were elicited across all seven mKRAS antigens, with >80% response rate to each individual KRAS mutation and 88% of patients generating responses to their own tumor-specific mutation 86.8% (66/76) of patients induced cytotoxic mKRAS-specific T cell responses; 75% (57/76) induced CD8 + T cells and 75% (57/76) induced CD4 + T cells mKRAS-specific T cell responses were observed across diverse HLA types, supporting the potential applicability of ELI-002 7P across a broad and genetically diverse patient population BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced additional immunogenicity data from the ongoing Phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in patients with mKRAS pancreatic ductal adenocarcinoma (“PDAC”) and new preclinical data on immunotherapy candidate ELI-004, for treatment of solid tumors. The data will be presented at the Society for Immunotherapy of Cancer (“SITC”) 2025 Annual Meeting (Nov. 7-8, 2025, in National Harbor, MD).

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025 in National Harbor, MD. CT-95 and CT-202 Highlights and Near-Term Milestones CT-95: Mesothelin x CD3 bispecific TCE CT-95 is avidity enhanced and affinity tuned to localize therapeutic activity to the tumor microenvironment.

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate cancer) Preclinical data reinforces broad potential of Bria-OTS+ platform across multiple indications PHILADELPHIA and VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company is presenting evidence of strong immune system engagement and anti-cancer activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, to be held November 7-9, 2025, in National Harbor, MD. Title: Redefining Cancer Vaccines: Bria-OTS+ Integrates Trained Innate Immunity and Adaptive Memory to Overcome Immune Resistance Abstract Number: 353 Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center Date: Friday, November.

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needs Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needs

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Reports Third Quarter 2025 Results.

SITE Centers Reports Third Quarter 2025 Results

Candel Therapeutics Inc (NASDAQ:CADL) will deliver three presentations at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). “Candel's presentations at SITC 2025 exemplify our innovative approach to the discovery and development of novel immunotherapies,” said CEO Paul Peter Tak.

Candel Therapeutics to highlight immunotherapy advances at SITC 2025

- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for CT-P72/ABP-102, a tetravalent bispecific antibody targeting HER2 and CD3, at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, being held November 6–10, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland.

Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40 th Annual SITC Meeting being held November 5-9, 2025 at National Harbor, MD.

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity  IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors

Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperformed select competitive antibodies in the class, including ivonescimab, in controlling tumor growth across multiple xenograft and syngeneic models.

Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

NEEDHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies to help patients fight cancer, today announced it will deliver three presentations at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, taking place November 5–9, 2025, in National Harbor, Maryland.

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Parker Pavilions.

SITE Centers Announces Sale of Parker Pavilions

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the Company will present a late-breaking update on clinical immunogenicity results from its ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients with mKRAS-driven pancreatic cancer and preclinical data from ELI-004 for the treatment of advanced solid tumors via two accepted poster presentations at the Society for Immunotherapy of Cancer's (“SITC”) 40th Anniversary Annual Meeting, taking place November 5–9, 2025, in National Harbor, Maryland. Presentation Details: Late-breaking Abstract (“LBA”) Poster Presentation Title: AMPLIFY-7P Phase 2: T cell responses induced by ELI-002 7P, a lymph node-targeted amphiphile therapeutic cancer vaccine in patients with KRAS mutated pancreatic ductal adenocarcinoma Presenter: Lisa McNeil, Ph.D.

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in China and sponsored by our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025) in National Harbor, Maryland (Washington D.C.

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology's immunotherapy platforms PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the National Cancer Institute (NCI) will present new clinical data at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in National Harbor, Maryland.

New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allianz Asset Management GmbH lowered its holdings in shares of Site Centers Corp. (NYSE: SITC) by 61.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 31,792 shares of the company's stock after selling 49,817 shares during the quarter. Allianz Asset Management

Allianz Asset Management GmbH Sells 49,817 Shares of Site Centers Corp. $SITC

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers' Third Quarter 2025 Earnings to be Released Wednesday, November 5, 2025.

SITE Centers' Third Quarter 2025 Earnings to be Released Wednesday, November 5, 2025

Site Centers Corp. (NYSE: SITC - Get Free Report) has received an average recommendation of "Hold" from the five research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The

Site Centers Corp. (NYSE:SITC) Receives Consensus Recommendation of “Hold” from Brokerages

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Corp. (NYSE: SITC), an owner of open-air shopping centers, today announced a special cash distribution on its common shares of $1.00 per common share payable on November 14, 2025 to shareholders of record at the close of business on October 31, 2025. About SITE Centers Corp. SITE Centers is an owner and manager of open-air shopping centers. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company,.

SITE Centers Announces Special Common Stock Distribution

SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced its participation in upcoming key financial, industry, scientific and medical conferences this fall, providing the opportunity to highlight continued momentum and recent developments among a broad range of stakeholder audiences. These conferences include: 4th Annual ROTH Healthcare Opportunities Conference October 9, 2025 - Metropolitan Club, New York City, New York Aptevo will participate in a panel on Acute Myeloid Leukemia titled "Novel AML Therapies Showing Clear Clinical Progress," discussing progress and recent trial outcomes of its lead asset, mipletamig, and sharing emerging evidence of its differentiated clinical profile in frontline AML-where strong safety, tolerability, and early efficacy continue to demonstrate meaningful potential for improved patient outcomes Biotechnology Innovation Organization (BIO)-Europe 2025 - 31st Annual International Partnering Conference November 3-5, 2025 (in-person); Digital Partnering Days: November 11-12, 2025 - Messe Wien Exhibition & Congress Center, Vienna, Austria The Business Development Team will be on-site and actively participating in meetings at the largest biotechnology meeting in Europe Society of Immunotherapy in Cancer (SITC) 2025 - 40th Anniversary Annual Meeting November 5-9, 2025 - Gaylord National Resort & Convention Center, National Harbor, Maryland Aptevo's R&D Team will present a poster highlighting a novel trispecific targeting Nectin-4, CD3 and CD40 to overcome the immunosuppressive the tumor microenvironment American Society of Hematology (ASH) 2025 - 67th American Society of Hematology Annual Meeting & Exposition December 6-9, 2025 - Orange County Convention Center, Orlando, Florida Interim results from the ongoing Phase 1b/2 RAINIER trial evaluating mip

Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company will have three poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, including the first clinical data on the novel CoREST inhibitor TNG260 in non-small cell lung cancer. SITC will be held November 5-9, 2025 in National Harbor, Maryland.

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the 40 th Annual SITC Meeting being held November 5-9, 2025 in National Harbor, MD.

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced updated data from its Phase 2 ASPEN-06 (NCT05002127) trial will be presented during a poster session at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland. The Phase 2 trial evaluated evorpacept, the Company's lead therapeutic candidate, in combination with HERCEPTIN® (trastuzumab), CYRAMZA® (ramucirumab) and paclitaxel, for patients with previously treated HER2-positive advanced gastric cancer (GC) and gastroesophageal junction (GEJ) cancer.

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – – CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC's upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 –

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland.

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that three posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland. Details for the poster presentations are as follows:

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced multiple upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 6-9, 2025 at the Gaylord National Convention Center in National Harbor, Maryland.

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. The details are listed below.

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Edgewater Towne Center.

SITE Centers Announces Sale of Edgewater Towne Center

HONG KONG , NOV. 7, 2025 /PRNEWSWIRE/ -- AKESO, INC. (HKEX: 9926.HK) PUBLISHED THE PRECLINICAL RESEARCH DATA FOR ITS NOVEL ANTAGONISTIC MONOCLONAL ANTIBODY TARGETING IL-1RAP, AK135, AT THE 40TH ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) HELD IN NATIONAL HARBOR, MARYLAND. THE RESULTS DEMONSTRATED THAT AK135 EFFECTIVELY TARGETS IL-1RAP AND BLOCKS THREE KEY PRO-INFLAMMATORY SIGNALING PATHWAYSIL-1, IL-33, AND IL-36 AT THEIR SOURCE, THEREBY HALTING THE TRANSMISSION OF INFLAMMATORY SIGNALS.

AKESO UNVEILS PROMISING PRECLINICAL DATA FOR IL-1RAP TARGETING ANTIBODY (AK135) AT SITC 2025

40% ORR IN HEAVILY PRE-TREATED PATIENTS WITH MSS MCRC WITHOUT LIVER METASTASES AND WITH HIGH PLASMA TUMOR MUTATIONAL BURDEN (TMB)

XILIO THERAPEUTICS ANNOUNCES LATE-BREAKING PHASE 2 DATA FOR VILASTOBART IN PATIENTS WITH MSS MCRC AND HIGH PLASMA TUMOR MUTATIONAL BURDEN AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING

PRECLINICAL DATA SUPPORT BEST-IN-CLASS POTENTIAL OF MASKED T CELL ENGAGER PROGRAMS AND PLATFORM UTILIZING XILIO'S ATACR AND SEECR FORMATS, INCLUDING EFFICIENT MASKING, POTENT ANTI-TUMOR ACTIVITY AND BROAD THERAPEUTIC INDEX PHASE 1 DATA FOR EFARINDODEKIN ALFA, A TUMOR-ACTIVATED IL-12, DEMONSTRATED PROMISING MONOTHERAPY ANTI-TUMOR ACTIVITY IN PATIENTS WITH ADVANCED SOLID TUMORS AND GENERALLY WELL-TOLERATED SAFETY PROFILE PHASE 2 DATA FOR VILASTOBART, A TUMOR-ACTIVATED, FC-ENHANCED ANTI-CTLA-4, SHOW POTENTIAL FOR CTDNA AS AN EARLY PREDICTOR FOR RESPONSE TO TREATMENT WITH VILASTOBART IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH MSS MCRC WALTHAM, MASS., NOV. 07, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED NEW DATA ACROSS ITS PORTFOLIO, INCLUDING PRECLINICAL DATA HIGHLIGHTING THE BEST-IN-CLASS POTENTIAL FOR XILIO'S MASKED T CELL ENGAGER PLATFORM AND PROGRAMS, AS WELL AS PHASE 1 DATA FOR EFARINDODEKIN ALFA, A TUMOR-ACTIVATED IL-12, AND PHASE 2 DATA RELATED TO CIRCULATING TUMOR DNA (CTDNA) FOR VILASTOBART, A TUMOR-ACTIVATED, FC-ENHANCED ANTI-CTLA-4.

XILIO THERAPEUTICS HIGHLIGHTS PORTFOLIO OF DIFFERENTIATED MASKED IMMUNOTHERAPIES AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING

NEW YORK, NOV. 07, 2025 (GLOBE NEWSWIRE) -- MINK THERAPEUTICS, INC. (NASDAQ: INKT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING ALLOGENEIC INVARIANT NATURAL KILLER T (ALLO-INKT) CELL THERAPIES TO RECONSTITUTE IMMUNITY TO TREAT CANCER AND IMMUNE DISORDERS, TODAY ANNOUNCED UPDATED CLINICAL RESULTS EVALUATING AGENT-797, ALONE AND IN COMBINATION WITH ANTI-PD-1 THERAPY, IN PATIENTS WITH ADVANCED SOLID TUMORS REFRACTORY TO ALL APPROVED TREATMENTS PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2025 (LATE BREAKING ABSTRACT #1344).

MINK THERAPEUTICS REPORTS DURABLE RESPONSES AND IMMUNE REACTIVATION WITH ALLO-INKT CELL THERAPY AGENT-797 IN PD-1REFRACTORY SOLID TUMORS AT SITC 2025

PRE-CLINICAL DATA FOR IO BIOTECH'S NEXT T-WIN VACCINE CANDIDATE, IO112 TARGETING ARGINASE 1, DEMONSTRATES ANTI-TUMOR ACTIVITY WITH DYNAMIC CHANGES IN THE TUMOR MICROENVIRONMENT (TME) DRIVEN BY THE VACCINE-TARGETED MODULATION OF IMMUNOSUPPRESSIVE MYELOID CELLS, INCLUDING TUMOR-ASSOCIATED MACROPHAGES (TAMS) PRE-CLINICAL DATA FOR IO BIOTECH'S ADDITIONAL T-WIN VACCINE CANDIDATE, IO170 TARGETING TRANSFORMING GROWTH FACTOR (TGF)-, DEMONSTRATES INDUCTION OF IMMUNE RESPONSES THAT COULD INHIBIT TUMOR GROWTH AND REDUCE LUNG METASTASIS DATA PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S ANNUAL MEETING NEW YORK, NOV. 07, 2025 (GLOBE NEWSWIRE) -- IO BIOTECH (NASDAQ: IOBT), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL, IMMUNE-MODULATORY, OFF-THE-SHELF THERAPEUTIC CANCER VACCINES, TODAY ANNOUNCED NEW PRE-CLINICAL DATA FOR IO BIOTECH'S NEXT VACCINE CANDIDATE, IO112, AND ADDITIONAL CANDIDATE, IO170, WILL BE PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S 40TH ANNUAL MEETING (SITC 2025) IN MARYLAND ON NOVEMBER 5-9, 2025. THIS NEW DATA IS EXTREMELY IMPORTANT FOR OUR DEVELOPMENT PATH AS IT POINTS TOWARD MORE POTENTIAL INDICATIONS FOR OUR NOVEL, IMMUNE-MODULATORY THERAPEUTIC VACCINES TO TREAT PATIENTS WITH A RANGE OF CANCERS, SAID MAI-BRITT ZOCCA, PHD, PRESIDENT AND CEO OF IO BIOTECH.

IO BIOTECH PRESENTS PRE-CLINICAL DATA HIGHLIGHTING THE POTENTIAL OF ADDITIONAL THERAPEUTIC CANCER VACCINE CANDIDATES AT THE 2025 ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

 CHS-114 DEMONSTRATED ROBUST AND SELECTIVE DEPLETION OF CCR8+ TREGS AS WELL AS FAVORABLE IMMUNE REMODELING IN TUMOR TISSUE FROM HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) PATIENTS 

COHERUS ONCOLOGY PRESENTS AT SITC CLINICAL MULTIOMIC BIOMARKER DATA FOR CHS-114, A HIGHLY SELECTIVE ANTI-CCR8 CYTOLYTIC ANTIBODY

SITC ABSTRACTS HIGHLIGHT UPDATED IMMUNOGENICITY RESULTS FROM THE PHASE 2 AMPLIFY-7P TRIAL OF ELI-002 7P AND PRECLINICAL DATA ON THE USE OF INTRATUMORAL ELI-004 (AMP-CPG) FOR SOLID TUMOR IMMUNOTHERAPY ELI-002 7P INDUCED MKRAS-SPECIFIC T CELL RESPONSES IN 99% OF EVALUABLE PATIENTS (89/90), DEMONSTRATING POTENT AND CONSISTENT IMMUNE ACTIVATION ROBUST IMMUNE RESPONSES WERE ELICITED ACROSS ALL SEVEN MKRAS ANTIGENS, WITH >80% RESPONSE RATE TO EACH INDIVIDUAL KRAS MUTATION AND 88% OF PATIENTS GENERATING RESPONSES TO THEIR OWN TUMOR-SPECIFIC MUTATION 86.8% (66/76) OF PATIENTS INDUCED CYTOTOXIC MKRAS-SPECIFIC T CELL RESPONSES; 75% (57/76) INDUCED CD8 + T CELLS AND 75% (57/76) INDUCED CD4 + T CELLS MKRAS-SPECIFIC T CELL RESPONSES WERE OBSERVED ACROSS DIVERSE HLA TYPES, SUPPORTING THE POTENTIAL APPLICABILITY OF ELI-002 7P ACROSS A BROAD AND GENETICALLY DIVERSE PATIENT POPULATION BOSTON, NOV. 07, 2025 (GLOBE NEWSWIRE) -- ELICIO THERAPEUTICS, INC. (NASDAQ: ELTX, ELICIO OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING A PIPELINE OF NOVEL IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED ADDITIONAL IMMUNOGENICITY DATA FROM THE ONGOING PHASE 2 AMPLIFY-7P TRIAL EVALUATING ELI-002 7P IN PATIENTS WITH MKRAS PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) AND NEW PRECLINICAL DATA ON IMMUNOTHERAPY CANDIDATE ELI-004, FOR TREATMENT OF SOLID TUMORS. THE DATA WILL BE PRESENTED AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2025 ANNUAL MEETING (NOV. 7-8, 2025, IN NATIONAL HARBOR, MD).

ELICIO THERAPEUTICS REPORTS ROBUST, CYTOLYTIC MKRAS-SPECIFIC T CELL RESPONSES ACROSS DIVERSE PATIENT HLA IN ONGOING PHASE 2 AMPLIFY-7P TRIAL OF ELI-002 7P AND NEW ELI-004 PRECLINICAL DATA AT SITC

NOVEL INDUCER T CELL ENGAGER PLATFORM DESIGNED TO MITIGATE SYSTEMIC TOXICITIES SEQUENTIAL DOSING OF INDUKINE MOLECULES IN PRECLINICAL MODEL SHOWED POTENT ANTITUMOR ACTIVITY WITH IMPROVED SAFETY FIRST-IN-KIND REAL-TIME PHARMACOKINETIC DATA IN A MOUSE TUMOR MODEL CONFIRMED WTX-124 SELECTIVE ACTIVATION IN TUMORS, SPARING HEALTHY TISSUE WATERTOWN, MASS., NOV. 07, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY SHARED PRECLINICAL DATA AT THE 2025 SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING, TAKING PLACE NOVEMBER 5-9, 2025, IN NATIONAL HARBOR, MARYLAND.

WEREWOLF THERAPEUTICS PRESENTS DATA EXPANDING ITS PREDATOR PLATFORM AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING

PHILADELPHIA, NOV. 07, 2025 (GLOBE NEWSWIRE) -- CONTEXT THERAPEUTICS INC. (CONTEXT OR THE COMPANY) (NASDAQ: CNTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING T CELL ENGAGING (TCE) BISPECIFIC ANTIBODIES FOR SOLID TUMORS, TODAY SHARED TWO POSTERS DISCUSSING THE COMPANY'S CT-95 AND CT-202 PROGRAMS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING, BEING HELD NOVEMBER 79, 2025 IN NATIONAL HARBOR, MD. CT-95 AND CT-202 HIGHLIGHTS AND NEAR-TERM MILESTONES CT-95: MESOTHELIN X CD3 BISPECIFIC TCE CT-95 IS AVIDITY ENHANCED AND AFFINITY TUNED TO LOCALIZE THERAPEUTIC ACTIVITY TO THE TUMOR MICROENVIRONMENT.

CONTEXT THERAPEUTICS HIGHLIGHTS CT-95 AND CT-202 PROGRAMS AT 2025 SITC ANNUAL MEETING

NEXT GENERATION BRIA-OTS+ PLATFORM DEMONSTRATES RAPID, POTENT AND DURABLE ANTI-CANCER ACTIVITY BY ACTIVATING BOTH INNATE AND ADAPTIVE IMMUNE RESPONSES INCREASED TUMOR CELL CYTOTOXICITY INDUCED BY BOTH BRIA-BRES+ (BREAST CANCER) AND BRIA-PROS+ (PROSTATE CANCER) PRECLINICAL DATA REINFORCES BROAD POTENTIAL OF BRIA-OTS+ PLATFORM ACROSS MULTIPLE INDICATIONS PHILADELPHIA AND VANCOUVER, BRITISH COLUMBIA, NOV. 07, 2025 (GLOBE NEWSWIRE) -- BRIACELL THERAPEUTICS CORP. (NASDAQ: BCTX, BCTXW, BCTXZ) (TSX: BCT) (BRIACELL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY THAT DEVELOPS NOVEL IMMUNOTHERAPIES TO TRANSFORM CANCER CARE, IS PLEASED TO ANNOUNCE THAT THE COMPANY IS PRESENTING EVIDENCE OF STRONG IMMUNE SYSTEM ENGAGEMENT AND ANTI-CANCER ACTIVITY OF ITS NEXT GENERATION BRIA-OTS+ PLATFORM IN PRECLINICAL MODELS AT A POSTER PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNIVERSARY ANNUAL MEETING, TO BE HELD NOVEMBER 7-9, 2025, IN NATIONAL HARBOR, MD. TITLE: REDEFINING CANCER VACCINES: BRIA-OTS+ INTEGRATES TRAINED INNATE IMMUNITY AND ADAPTIVE MEMORY TO OVERCOME IMMUNE RESISTANCE ABSTRACT NUMBER: 353 LOCATION: PRINCE GEORGE ABC EXHIBIT HALLS, GAYLORD NATIONAL RESORT AND CONVENTION CENTER DATE: FRIDAY, NOVEMBER.

BRIACELL PRESENTS ROBUST ANTI-CANCER ACTIVITY OF BRIA-OTS+ AT SITC 2025

TETRA-VALENT T-CELL ENGAGER DESIGNED TO ADDRESS SHORTFALLS OF BI-SPECIFIC T-CELL ENGAGERS (BITE) RELATED TO MANUFACTURABILITY, SAFETY PROFILE, AND ABILITY TO TREAT A WIDE SPECTRUM OF SOLID TUMORS TETRA-VALENT T-CELL ENGAGER DESIGNED TO ADDRESS SHORTFALLS OF BI-SPECIFIC T-CELL ENGAGERS (BITE) RELATED TO MANUFACTURABILITY, SAFETY PROFILE, AND ABILITY TO TREAT A WIDE SPECTRUM OF SOLID TUMORS

HCW BIOLOGICS PRESENTS PRECLINICAL DATA FOR TRBC-BASED T-CELL ENGAGER PROGRAM AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING

LEPTOMENINGEAL METASTASES DISEASE SESSION FEATURES NOVEL TREATMENTS IN THE HORIZON, REYOBIQ AND RESPECT-LM, AND FUTURE DIRECTIONS AND NEEDS LEPTOMENINGEAL METASTASES DISEASE SESSION FEATURES NOVEL TREATMENTS IN THE HORIZON, REYOBIQ AND RESPECT-LM, AND FUTURE DIRECTIONS AND NEEDS

PLUS THERAPEUTICS HIGHLIGHTS RESPECT-LM CLINICAL TRIAL RESULTS AT 40TH SITC ANNUAL MEETING, MELANOMA RESEARCH FOUNDATION BRAIN METASTASES SUMMIT 4.0

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS REPORTS THIRD QUARTER 2025 RESULTS.

SITE CENTERS REPORTS THIRD QUARTER 2025 RESULTS

BURLINGTON, MASS., NOV. 04, 2025 (GLOBE NEWSWIRE) -- ABPRO CORPORATION (NASDAQ: ABP) (ABPRO) AND CELLTRION, INC. (CELLTRION) TODAY ANNOUNCED THAT THEY WILL PRESENT NEW PRECLINICAL DATA FOR CT-P72/ABP-102, A TETRAVALENT BISPECIFIC ANTIBODY TARGETING HER2 AND CD3, AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 2025 ANNUAL MEETING, BEING HELD NOVEMBER 610, 2025, AT THE GAYLORD NATIONAL RESORT AND CONVENTION CENTER IN NATIONAL HARBOR, MARYLAND.

ABPRO AND CELLTRION TO PRESENT PRECLINICAL DATA FOR CT-P72/ABP-102 AT SITC 2025, HIGHLIGHTING A NEXT-GENERATION HER2CD3 T-CELL ENGAGER

- CX-801 (PROBODY INTERFERON ALPHA-2B) PHASE 1 DATA DEMONSTRATE ACTIVATION OF TUMOR-SELECTIVE INTERFERON SIGNALING IN PATIENTS WITH ADVANCED MELANOMA -

CYTOMX THERAPEUTICS TO PRESENT CX-801 PHASE 1 MONOTHERAPY BIOMARKER DATA AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

CR-001 DEMONSTRATED COOPERATIVE PHARMACOLOGY AND ROBUST ANTI-TUMOR ACTIVITY IND SUBMISSION FOR CR-001 ON TRACK FOR FOURTH QUARTER OF 2025 TO SUPPORT INITIATION OF GLOBAL PHASE 1 TRIAL IN PATIENTS WITH SOLID TUMORS

CRESCENT BIOPHARMA TO PRESENT PRECLINICAL DATA FOR CR-001, A PD-1 X VEGF BISPECIFIC ANTIBODY, AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC)40TH ANNUAL MEETING

OCALA, FLA., NOV. 04, 2025 (GLOBE NEWSWIRE) -- AIM IMMUNOTECH INC. (NYSE AMERICAN: AIM)(AIM OR THE COMPANY) TODAY ANNOUNCED THAT DATA FROM THE COMPLETED PHASE 2 CISPLATIN-RESISTANT ADVANCED RECURRENT OVARIAN CANCER CLINICAL STUDY UTILIZING AMPLIGEN (RINTATOLIMOD) WAS ACCEPTED IN A LATE-BREAKING ABSTRACT AT THE 40 TH ANNUAL SITC MEETING BEING HELD NOVEMBER 5-9, 2025 AT NATIONAL HARBOR, MD.

AIM IMMUNOTECH ANNOUNCES LATE BREAKING ABSTRACT FROM UNIVERSITY OF PITTSBURGH MEDICAL CENTER ACCEPTED FOR PRESENTATION AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING

CTX-10726 DEMONSTRATED POTENT, SIMULTANEOUS INHIBITION OF TUMOR ANGIOGENESIS AND PD-1-MEDIATED IMMUNE SUPPRESSION, AND ELIMINATED TUMORS IN MULTIPLE PRECLINICAL STUDIES. IN VIVO, CTX-10726 OUTPERFORMED SELECT COMPETITIVE ANTIBODIES IN THE CLASS, INCLUDING IVONESCIMAB, IN CONTROLLING TUMOR GROWTH ACROSS MULTIPLE XENOGRAFT AND SYNGENEIC MODELS.

COMPASS THERAPEUTICS PRESENTS PRECLINICAL DATA ON CTX-10726, A DIFFERENTIATED PD-1 X VEGF-A BISPECIFIC ANTIBODY, AT THE 40TH SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

NEEDHAM, MASS., NOV. 04, 2025 (GLOBE NEWSWIRE) -- CANDEL THERAPEUTICS, INC. (CANDEL OR THE COMPANY) (NASDAQ: CADL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIMODAL BIOLOGICAL IMMUNOTHERAPIES TO HELP PATIENTS FIGHT CANCER, TODAY ANNOUNCED IT WILL DELIVER THREE PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNIVERSARY ANNUAL MEETING, TAKING PLACE NOVEMBER 59, 2025, IN NATIONAL HARBOR, MARYLAND.

CANDEL THERAPEUTICS SHOWCASES IMMUNOTHERAPY LEADERSHIP AT SITC 2025, DEMONSTRATING INTEGRATION OF CLINICAL INNOVATION, MULTI-OMICS, AND ARTIFICIAL INTELLIGENCE TO ADVANCE NEXT-GENERATION IMMUNOTHERAPIES IN SOLID TUMORS

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS ANNOUNCES SALE OF PARKER PAVILIONS.

SITE CENTERS ANNOUNCES SALE OF PARKER PAVILIONS

BOSTON, NOV. 03, 2025 (GLOBE NEWSWIRE) -- ELICIO THERAPEUTICS, INC. (NASDAQ: ELTX, ELICIO OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING A PIPELINE OF NOVEL IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PRESENT A LATE-BREAKING UPDATE ON CLINICAL IMMUNOGENICITY RESULTS FROM ITS ONGOING PHASE 2 AMPLIFY-7P TRIAL OF ELI-002 IN PATIENTS WITH MKRAS-DRIVEN PANCREATIC CANCER AND PRECLINICAL DATA FROM ELI-004 FOR THE TREATMENT OF ADVANCED SOLID TUMORS VIA TWO ACCEPTED POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNIVERSARY ANNUAL MEETING, TAKING PLACE NOVEMBER 59, 2025, IN NATIONAL HARBOR, MARYLAND. PRESENTATION DETAILS: LATE-BREAKING ABSTRACT (LBA) POSTER PRESENTATION TITLE: AMPLIFY-7P PHASE 2: T CELL RESPONSES INDUCED BY ELI-002 7P, A LYMPH NODE-TARGETED AMPHIPHILE THERAPEUTIC CANCER VACCINE IN PATIENTS WITH KRAS MUTATED PANCREATIC DUCTAL ADENOCARCINOMA PRESENTER: LISA MCNEIL, PH.D.

ELICIO THERAPEUTICS TO PRESENT CLINICAL AND PRECLINICAL DATA AT THE SITC 2025 ANNUAL MEETING

MIAMI--(BUSINESS WIRE)---- $SMMT--SUMMIT THERAPEUTICS INC. (NASDAQ: SMMT) (SUMMIT, WE, OR THE COMPANY) TODAY ANNOUNCED THAT RESULTS FROM THE PHASE III HARMONI-A TRIAL, CONDUCTED IN CHINA AND SPONSORED BY OUR PARTNER, AKESO, INC. (AKESO, HKEX CODE: 9926.HK), FEATURING THE NOVEL, POTENTIAL FIRST-IN-CLASS INVESTIGATIONAL BISPECIFIC ANTIBODY, IVONESCIMAB, WILL BE PRESENTED AS PART OF THE ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC 2025) IN NATIONAL HARBOR, MARYLAND (WASHINGTON D.C.

OVERALL SURVIVAL DATA FROM HARMONI-A, FEATURING IVONESCIMAB IN COMBINATION WITH CHEMOTHERAPY VS. CHEMOTHERAPY IN 2L+ TREATMENT OF PATIENTS WITH EGFRM NSCLC IN CHINA, TO BE SHOWCASED AT SITC 2025

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS' THIRD QUARTER 2025 EARNINGS TO BE RELEASED WEDNESDAY, NOVEMBER 5, 2025.

SITE CENTERS' THIRD QUARTER 2025 EARNINGS TO BE RELEASED WEDNESDAY, NOVEMBER 5, 2025

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS CORP. (NYSE: SITC), AN OWNER OF OPEN-AIR SHOPPING CENTERS, TODAY ANNOUNCED A SPECIAL CASH DISTRIBUTION ON ITS COMMON SHARES OF $1.00 PER COMMON SHARE PAYABLE ON NOVEMBER 14, 2025 TO SHAREHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON OCTOBER 31, 2025. ABOUT SITE CENTERS CORP. SITE CENTERS IS AN OWNER AND MANAGER OF OPEN-AIR SHOPPING CENTERS. THE COMPANY IS A SELF-ADMINISTERED AND SELF-MANAGED REIT OPERATING AS A FULLY INTEGRATED REAL ESTATE COMPANY,.

SITE CENTERS ANNOUNCES SPECIAL COMMON STOCK DISTRIBUTION

SEATTLE, WASHINGTON / ACCESS NEWSWIRE / OCTOBER 8, 2025 / APTEVO THERAPEUTICS ("APTEVO" OR THE "COMPANY") (NASDAQ:APVO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL BISPECIFIC AND TRISPECIFIC IMMUNO-ONCOLOGY THERAPEUTICS, TODAY ANNOUNCED ITS PARTICIPATION IN UPCOMING KEY FINANCIAL, INDUSTRY, SCIENTIFIC AND MEDICAL CONFERENCES THIS FALL, PROVIDING THE OPPORTUNITY TO HIGHLIGHT CONTINUED MOMENTUM AND RECENT DEVELOPMENTS AMONG A BROAD RANGE OF STAKEHOLDER AUDIENCES. THESE CONFERENCES INCLUDE: 4TH ANNUAL ROTH HEALTHCARE OPPORTUNITIES CONFERENCE OCTOBER 9, 2025 - METROPOLITAN CLUB, NEW YORK CITY, NEW YORK APTEVO WILL PARTICIPATE IN A PANEL ON ACUTE MYELOID LEUKEMIA TITLED "NOVEL AML THERAPIES SHOWING CLEAR CLINICAL PROGRESS," DISCUSSING PROGRESS AND RECENT TRIAL OUTCOMES OF ITS LEAD ASSET, MIPLETAMIG, AND SHARING EMERGING EVIDENCE OF ITS DIFFERENTIATED CLINICAL PROFILE IN FRONTLINE AML-WHERE STRONG SAFETY, TOLERABILITY, AND EARLY EFFICACY CONTINUE TO DEMONSTRATE MEANINGFUL POTENTIAL FOR IMPROVED PATIENT OUTCOMES BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)-EUROPE 2025 - 31ST ANNUAL INTERNATIONAL PARTNERING CONFERENCE NOVEMBER 3-5, 2025 (IN-PERSON); DIGITAL PARTNERING DAYS: NOVEMBER 11-12, 2025 - MESSE WIEN EXHIBITION & CONGRESS CENTER, VIENNA, AUSTRIA THE BUSINESS DEVELOPMENT TEAM WILL BE ON-SITE AND ACTIVELY PARTICIPATING IN MEETINGS AT THE LARGEST BIOTECHNOLOGY MEETING IN EUROPE SOCIETY OF IMMUNOTHERAPY IN CANCER (SITC) 2025 - 40TH ANNIVERSARY ANNUAL MEETING NOVEMBER 5-9, 2025 - GAYLORD NATIONAL RESORT & CONVENTION CENTER, NATIONAL HARBOR, MARYLAND APTEVO'S R&D TEAM WILL PRESENT A POSTER HIGHLIGHTING A NOVEL TRISPECIFIC TARGETING NECTIN-4, CD3 AND CD40 TO OVERCOME THE IMMUNOSUPPRESSIVE THE TUMOR MICROENVIRONMENT AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2025 - 67TH AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING & EXPOSITION DECEMBER 6-9, 2025 - ORANGE COUNTY CONVENTION CENTER, ORLANDO, FLORIDA INTERIM RESULTS FROM THE ONGOING PHASE 1B/2 RAINIER TRIAL EVALUATING MIP

APTEVO PRESENTING SCIENTIFIC AND CLINICAL UPDATES AT SITC AND ASH, ALSO PARTICIPATING IN LEADING FINANCIAL AND INDUSTRY CONFERENCES IN THE FOURTH QUARTER

BOSTON, OCT. 06, 2025 (GLOBE NEWSWIRE) -- TANGO THERAPEUTICS, INC. (NASDAQ: TNGX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO DISCOVERING AND DELIVERING THE NEXT GENERATION OF PRECISION CANCER MEDICINES, TODAY ANNOUNCED THAT THE COMPANY WILL HAVE THREE POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2025, INCLUDING THE FIRST CLINICAL DATA ON THE NOVEL COREST INHIBITOR TNG260 IN NON-SMALL CELL LUNG CANCER. SITC WILL BE HELD NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MARYLAND.

TANGO THERAPEUTICS TO PRESENT FIRST CLINICAL DATA FROM TNG260 AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING 2025

BOSTON AND LONDON, OCT. 03, 2025 (GLOBE NEWSWIRE) -- AKARI THERAPEUTICS, PLC (NASDAQ: AKTX), AN ONCOLOGY BIOTECHNOLOGY COMPANY DEVELOPING NOVEL PAYLOAD ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED ITS ABSTRACT HAS BEEN ACCEPTED FOR ORAL PRESENTATION AT THE 40 TH ANNUAL SITC MEETING BEING HELD NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MD.

AKARI THERAPEUTICS ANNOUNCES ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING

SOUTH SAN FRANCISCO, CALIF., OCT. 03, 2025 (GLOBE NEWSWIRE) -- ALX ONCOLOGY HOLDINGS INC., (ALX ONCOLOGY OR THE COMPANY) (NASDAQ: ALXO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING A PIPELINE OF NOVEL THERAPIES DESIGNED TO TREAT CANCER AND EXTEND PATIENTS' LIVES, TODAY ANNOUNCED UPDATED DATA FROM ITS PHASE 2 ASPEN-06 (NCT05002127) TRIAL WILL BE PRESENTED DURING A POSTER SESSION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING TAKING PLACE NOVEMBER 59, 2025, IN NATIONAL HARBOR, MARYLAND. THE PHASE 2 TRIAL EVALUATED EVORPACEPT, THE COMPANY'S LEAD THERAPEUTIC CANDIDATE, IN COMBINATION WITH HERCEPTIN(TRASTUZUMAB), CYRAMZA(RAMUCIRUMAB) AND PACLITAXEL, FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE ADVANCED GASTRIC CANCER (GC) AND GASTROESOPHAGEAL JUNCTION (GEJ) CANCER.

ALX ONCOLOGY TO PRESENT UPDATED DATA FROM PHASE 2 ASPEN-06 TRIAL, HIGHLIGHTING CD47 EXPRESSION AS A PREDICTIVE BIOMARKER IN HER2+ GASTRIC CANCER, AT 40TH SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

NEEDHAM, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- CANDEL THERAPEUTICS, INC. (CANDEL OR THE COMPANY) (NASDAQ: CADL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MULTIMODAL BIOLOGICAL IMMUNOTHERAPIES TO HELP PATIENTS FIGHT CANCER, TODAY ANNOUNCED THE COMPANY WILL PRESENT INSIGHTS FROM ITS ENLIGHTEN DISCOVERY PLATFORM, AND ADDITIONAL DATA FROM THE CAN-2409 (AGLATIMAGENE BESADENOVEC) PROGRAM IN NON-SMALL CELL LUNG CANCER (NSCLC), THROUGH TWO ACCEPTED POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNIVERSARY ANNUAL MEETING, TAKING PLACE NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MARYLAND.

CANDEL THERAPEUTICS TO PRESENT AT THE SITC 2025 ANNUAL MEETING

 CHS-114, AN ANTI-CCR8 CYTOLYTIC ANTIBODY, WILL ALSO BE FEATURED IN SITC'S UPCOMING WEBINAR SERIES TARGETS FOR CANCER IO: A DEEP DIVE ON OCTOBER 22, 2025   CHS-114, AN ANTI-CCR8 CYTOLYTIC ANTIBODY, WILL ALSO BE FEATURED IN SITC'S UPCOMING WEBINAR SERIES TARGETS FOR CANCER IO: A DEEP DIVE ON OCTOBER 22, 2025 

COHERUS ONCOLOGY ANNOUNCES POSTER PRESENTATION AT THE 40TH ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

WALTHAM, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED MULTIPLE UPCOMING POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING, TAKING PLACE FROM NOVEMBER 6-9, 2025 AT THE GAYLORD NATIONAL CONVENTION CENTER IN NATIONAL HARBOR, MARYLAND.

XILIO THERAPEUTICS ANNOUNCES UPCOMING PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING

WATERTOWN, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED THAT THREE POSTERS WILL BE PRESENTED AT THE UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING, TAKING PLACE NOVEMBER 5-9, 2025, IN NATIONAL HARBOR, MARYLAND. DETAILS FOR THE POSTER PRESENTATIONS ARE AS FOLLOWS:

WEREWOLF THERAPEUTICS TO PRESENT POSTERS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING

PHILADELPHIA AND VANCOUVER, BRITISH COLUMBIA, OCT. 03, 2025 (GLOBE NEWSWIRE) -- BRIACELL THERAPEUTICS CORP. (NASDAQ: BCTX, BCTXW, BCTXZ) (TSX: BCT) (BRIACELL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY THAT DEVELOPS NOVEL IMMUNOTHERAPIES TO TRANSFORM CANCER CARE, IS PLEASED TO ANNOUNCE THAT THE COMPANY WILL BE PRESENTING PRECLINICAL BRIA-OTS+ DATA AT A POSTER PRESENTATION AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNIVERSARY ANNUAL MEETING, HELD NOVEMBER 7-9, 2025, IN NATIONAL HARBOR, MD. THE DETAILS ARE LISTED BELOW.

BRIACELL TO PRESENT BRIA-OTS+ PRECLINICAL DATA AT SITC 2025 ANNUAL MEETING

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS ANNOUNCES SALE OF EDGEWATER TOWNE CENTER.

SITE Centers

SITC

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

SITC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

SITC